132 related articles for article (PubMed ID: 35328255)
1. Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response.
Trifan A; Stratina E; Rotaru A; Stafie R; Zenovia S; Nastasa R; Huiban L; Sfarti C; Cojocariu C; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Stanciu C
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328255
[TBL] [Abstract][Full Text] [Related]
2. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
[TBL] [Abstract][Full Text] [Related]
3. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
[TBL] [Abstract][Full Text] [Related]
4. The effect of different direct antivirals on hepatic steatosis in nondiabetic and naïve hepatitis C-infected Egyptian patients.
El-Ghandour A; Youssif T; Ibrahim W; Abdelsattar HA; Bawady SAE; Wagih M; El-Nakeep S
Egypt J Intern Med; 2023; 35(1):12. PubMed ID: 36816629
[TBL] [Abstract][Full Text] [Related]
5. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
[TBL] [Abstract][Full Text] [Related]
6. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response.
Hsieh YC; Lee KC; Su CW; Lan KH; Huo TI; Wang YJ; Huang HC; Lin HC; Chu CJ; Huang YH; Hou MC
J Chin Med Assoc; 2021 May; 84(5):472-477. PubMed ID: 33742989
[TBL] [Abstract][Full Text] [Related]
7. The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
Lee YC; Hu TH; Hung CH; Lu SN; Chen CH; Wang JH
PLoS One; 2019; 14(4):e0214323. PubMed ID: 30939158
[TBL] [Abstract][Full Text] [Related]
8. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
[TBL] [Abstract][Full Text] [Related]
9. The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection.
Johnson LP; Sterling RK
Biology (Basel); 2020 Apr; 9(4):. PubMed ID: 32344543
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center.
Sung JC; Bosh C; Wyatt B; Miller M; Harty A; Del Bello D; Knight S; Dieterich DT; Perumalswami PV; Branch AD
J Viral Hepat; 2020 Apr; 27(4):350-359. PubMed ID: 31742821
[TBL] [Abstract][Full Text] [Related]
11. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.
Shousha HI; Abdelaziz RA; Azab SM; Khairy M; Afifi SA; Mehrez MI; Eshra MA; Abdelrahim AY
J Med Virol; 2018 Jun; 90(6):1099-1105. PubMed ID: 29469217
[TBL] [Abstract][Full Text] [Related]
12. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
Cespiati A; Petta S; Lombardi R; Di Marco V; Calvaruso V; Bertelli C; Pisano G; Fatta E; Sigon G; Iuculano F; Crapanzano L; Gibilaro G; Francione P; Craxì A; Fargion S; Fracanzani AL
Dig Liver Dis; 2021 Oct; 53(10):1301-1307. PubMed ID: 33214063
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt.
Abdelbary MS; Samir R; El-Nahaas SM; Shahin RMH; El-Sayed M; Gaber Y; Tantawi O; Zayed NA; Yosry A
J Clin Exp Hepatol; 2022; 12(5):1276-1284. PubMed ID: 36157140
[TBL] [Abstract][Full Text] [Related]
14. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.
Tag-Adeen M; Sabra AM; Akazawa Y; Ohnita K; Nakao K
Hepat Med; 2017; 9():45-53. PubMed ID: 29062242
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Impact of Direct-Acting Antivirals on Liver Fibrosis and Survival in HCV-Infected Liver Transplant Recipients.
Gambato M; Manuli C; Lynch EN; Battistella S; Germani G; Senzolo M; Zanetto A; Ferrarese A; Vitale A; Gringeri E; Cillo U; Burra P; Russo FP
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632044
[TBL] [Abstract][Full Text] [Related]
16. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter.
Shimizu K; Soroida Y; Sato M; Hikita H; Kobayashi T; Endo M; Sato M; Gotoh H; Iwai T; Tateishi R; Koike K; Yatomi Y; Ikeda H
Sci Rep; 2018 May; 8(1):7845. PubMed ID: 29777191
[TBL] [Abstract][Full Text] [Related]
17. Response to 'hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center'.
Sung JC; Wyatt BE; Perumalswami PV; Branch AD
J Viral Hepat; 2020 Dec; 27(12):1502-1503. PubMed ID: 32841428
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.
Mauss S; Buendgens L; Christensen S; Ingiliz P; Berger F; Hüppe D; Simon KG; Lutz T; Schewe K; Boesecke C; Tacke F
Z Gastroenterol; 2019 Feb; 57(2):139-147. PubMed ID: 30754058
[TBL] [Abstract][Full Text] [Related]
19. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
PLoS One; 2018; 13(12):e0209615. PubMed ID: 30576386
[TBL] [Abstract][Full Text] [Related]
20. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
